NASHVILLE–(BUSINESS WIRE)–Oct 28, 2022–
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it will release its financial results for the third quarter ended September 30, 2022, on Monday, November 14, 2022, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.
Conference Call Details: |
|
Date: | Monday, November 14, 2022 |
Time: | 4:45 p.m. Eastern time |
Participant Dial-in: | 1-833-953-2434 (U.S.) |
Replay Dial-in (Passcode 7735845): (telephonic replay through November 21, 2022) | 1-877-344-7529 (U.S.) |
Webcast: (online replay through February 14, 2023) |
About Harrow
Harrow (Nasdaq: HROW) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies that are accessible and affordable. For more information about Harrow, including investor-related materials, please visit the corporate website, harrowinc.com, or Harrow’s LinkedIn page.
View source version on businesswire.com:https://www.businesswire.com/news/home/20221027005179/en/
CONTACT: Jamie Webb, Director of Communications and Investor Relations
615-733-4737
KEYWORD: UNITED STATES NORTH AMERICA TENNESSEE
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL OPTICAL MEDICAL SUPPLIES SURGERY HEALTH FDA CLINICAL TRIALS
SOURCE: Harrow
Copyright Business Wire 2022.
PUB: 10/28/2022 08:00 AM/DISC: 10/28/2022 08:01 AM
Copyright Business Wire 2022.
